Compounds > niacinamide
Page last updated: 2024-10-19

niacinamide and Brain Neoplasms

niacinamide has been researched along with Brain Neoplasms in 74 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research Excerpts

ExcerptRelevanceReference
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."9.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
"A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted."9.19Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. ( Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H, 2014)
"We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect."9.17Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013)
"Sorafenib can be safely combined with radiation and temozolomide in patients with high-grade glioma and with radiation alone in patients with recurrent glioma."9.17A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme."9.14Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010)
"Prospective evaluation of the toxicity and efficacy of carbogen and nicotinamide with external beam radiotherapy in the management of inoperable glioblastoma."9.10Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. ( Baillet, F; Chiras, J; Delattre, JY; Hoang-Xuan, K; Mazeron, JJ; Noël, G; Simon, JM, 2003)
"A three-step phase I/II trial associating accelerated radiotherapy with carbogen (step 1, ARCO), with nicotinamide (step 2, ARN), or with both (step 3, ARCON) was conducted, the aim of which was to overcome the effects of proliferation and hypoxia as potential causes of tumor radioresistance in glioblastoma multiforme."9.09Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. ( Bernier, J; Bolla, M; Denekamp, J; Greiner, R; Hulshof, M; Miralbell, R; Mirimanoff, RO; Mornex, F; Pierart, M; Rojas, AM; Storme, G; van Glabbeke, M, 1999)
"No significant influence of carbogen and/or NAM on tumour perfusion and normal brain perfusion could be detected with SPECT in patients with glioblastoma."9.08Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. ( Booij, J; Bosch, DA; González González, D; Hulshof, MC; Rehmann, CJ; van Royen, EA, 1998)
"The effect of sorafenib on signaling, proliferation, radiosensitivity, chemosensitivity and radiochemosensitivity was analyzed in six glioblastoma cell lines using Western blot, proliferation- and colony formation assays."7.83Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. ( Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N, 2016)
"We examined the effects of sorafenib, VK1 or their combination on the proliferation and apoptosis of human malignant glioma cell lines (BT325 and U251) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry and 4',6-diamidino-2-phenylindole (DAPI) assay."7.78Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012)
"This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice."7.71Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice. ( Buchegger, F; Coucke, PA; Mirimanoff, RO; Sun, LQ, 2001)
"Sorafenib was administered twice daily at 200 mg/m(2)/dose (maximum of 400 mg/dose) in continuous 28-day cycles."6.79Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. ( Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D, 2014)
" Pharmacokinetic sampling was performed during cycle 1."6.78NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
" The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly."6.77Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."6.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."6.76Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis."5.39Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A, 2013)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."5.38Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. ( Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R, 2012)
" In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)."5.29Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995)
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."5.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
"A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted."5.19Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. ( Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H, 2014)
"We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect."5.17Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013)
"Sorafenib can be safely combined with radiation and temozolomide in patients with high-grade glioma and with radiation alone in patients with recurrent glioma."5.17A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme."5.14Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010)
"Prospective evaluation of the toxicity and efficacy of carbogen and nicotinamide with external beam radiotherapy in the management of inoperable glioblastoma."5.10Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. ( Baillet, F; Chiras, J; Delattre, JY; Hoang-Xuan, K; Mazeron, JJ; Noël, G; Simon, JM, 2003)
"A three-step phase I/II trial associating accelerated radiotherapy with carbogen (step 1, ARCO), with nicotinamide (step 2, ARN), or with both (step 3, ARCON) was conducted, the aim of which was to overcome the effects of proliferation and hypoxia as potential causes of tumor radioresistance in glioblastoma multiforme."5.09Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. ( Bernier, J; Bolla, M; Denekamp, J; Greiner, R; Hulshof, M; Miralbell, R; Mirimanoff, RO; Mornex, F; Pierart, M; Rojas, AM; Storme, G; van Glabbeke, M, 1999)
"No significant influence of carbogen and/or NAM on tumour perfusion and normal brain perfusion could be detected with SPECT in patients with glioblastoma."5.08Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. ( Booij, J; Bosch, DA; González González, D; Hulshof, MC; Rehmann, CJ; van Royen, EA, 1998)
"The effect of sorafenib on signaling, proliferation, radiosensitivity, chemosensitivity and radiochemosensitivity was analyzed in six glioblastoma cell lines using Western blot, proliferation- and colony formation assays."3.83Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. ( Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N, 2016)
"We examined the effects of sorafenib, VK1 or their combination on the proliferation and apoptosis of human malignant glioma cell lines (BT325 and U251) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry and 4',6-diamidino-2-phenylindole (DAPI) assay."3.78Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012)
" Forty-eight male rats bearing a 9L gliosarcoma were randomized in untreated and treated (sorafenib) groups."3.78Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model. ( Barbier, EL; Bouchet, A; Christen, T; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Serduc, R, 2012)
"This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice."3.71Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice. ( Buchegger, F; Coucke, PA; Mirimanoff, RO; Sun, LQ, 2001)
"Eligible adults had 1-4 brain metastases from solid malignancies."2.84A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. ( Arneson, K; Attia, A; Chakravarthy, AB; Cmelak, AJ; Horn, L; Mondschein, J; Niermann, K; Puzanov, I; Stavas, M; Xia, F, 2017)
" Overall, adverse event rates were generally similar between the treatment arms."2.80SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. ( Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U, 2015)
"Sorafenib was administered twice daily at 200 mg/m(2)/dose (maximum of 400 mg/dose) in continuous 28-day cycles."2.79Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. ( Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D, 2014)
"Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas."2.79Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ( Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014)
" Pharmacokinetic sampling was performed during cycle 1."2.78NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
" The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly."2.77Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."2.76Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."2.76Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"The overall incidence of brain metastases in patients receiving sorafenib was 3% (2 of 70 patients) compared with 12% (8 of 69 patients) in patients receiving placebo (P < 0."2.75Incidence of brain metastases in renal cell carcinoma treated with sorafenib. ( Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J, 2010)
"A 64-year-old woman with metastatic breast cancer on follow-up had suspicious recurrent brain metastases."1.5618F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer. ( Alfeeli, M; Fathallah, W; Marafi, F; Sasikumar, A, 2020)
"Brain metastases are a common consequence of advanced lung cancer, resulting in cranial neuropathies and increased mortality."1.51A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. ( Hoj, JP; Mayro, B; Pendergast, AM, 2019)
"Sorafenib is a multikinase inhibitor that induces apoptosis of melanoma cells in vitro."1.43Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3. ( Brandon, VL; Chen, MY; Hsu, LC; Jandial, R; Jove, R; Li, G; Lin, J; Yang, F; Yin, Y; Zou, Z, 2016)
"Treatment of brain cancer cells with [sorafenib + lapatinib] enhanced radiation toxicity."1.42Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. ( Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S, 2015)
"Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy."1.40Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( Adamski, J; Agnihotri, S; Barszczyk, M; Buczkowicz, P; Castelo-Branco, P; Dirks, PB; Elizabeth, C; Golbourn, B; Hawkins, C; Li, XN; Luu, B; Mack, SC; Mangerel, J; Morrison, A; Nethery-Brokx, K; Pajovic, S; Ramaswamy, V; Remke, M; Rutka, JT; Tabori, U; Taylor, MD; Van Meter, T; Yu, M, 2014)
"Targeted therapies in metastatic renal cell carcinoma (mRCC) have been approved based on registration clinical trials that have strict eligibility criteria."1.40Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. ( Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T, 2014)
"The incidence of brain metastases per month in patients not treated with TKI therapy was 1."1.39Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. ( Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M, 2013)
"Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis."1.39Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A, 2013)
"Forty-seven patients had brain metastases at the start of first-line anti-vascular endothelial growth factor therapy, and the rest developed metastases during follow-up."1.39Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. ( Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM, 2013)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."1.38Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. ( Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R, 2012)
"We analyzed renal cell carcinoma (RCC) brain metastasis (BM) risk factors and compared BM occurrence in metastatic RCC (mRCC) treated with or without anti-angiogenic agents (AA)."1.38Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? ( Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L, 2012)
"Advanced or metastatic renal carcinoma represents a frequent disease in oncologic practice."1.36[Advanced renal carcinomas with special situations. How to treat them?]. ( Culine, S; Patard, JJ; Pouessel, D, 2010)
"We are presenting a case of renal cell carcinoma with multiple brain metastases that was successfully treated with multimodal therapy including a new type of medication."1.35Successful treatment of a brain-metastasized renal cell carcinoma. ( Johnston, KW; Walid, MS, 2009)
"Patients with renal cell and breast carcinoma metastases to the brain were identified from the prospective database at the Penn State Hershey Medical Center and Penn State Cancer Institute."1.35Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. ( Hill, KL; Lipson, AC; Sheehan, JM, 2009)
"To report the high incidence of intracerebral hemorrhage (ICH) in patients with metastatic renal cell carcinoma (RCC) treated with the tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR)."1.35High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. ( Culine, S; Pouessel, D, 2008)
"Malignant schwannomas or malignant peripheral nerve sheath tumors (MPNST) represent approximately 10% of all soft tissue sarcomas."1.35Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. ( Fenning, R; Gudena, V; Kizziah, M; Montero, AJ; Post, G; Verma, N, 2008)
"Malignant primary brain tumors have hitherto been incurable."1.30Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors. ( Brun, A; Kjellén, E; Pero, RW; Persson, RB; Salford, LG, 1997)
" In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)."1.29Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995)
"The pharmacokinetic properties of nicotinamide and its tolerance were studied in seven patients affected by glioblastoma multiforme and treated with two fractions per day of radiation therapy."1.29Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. ( Caciagli, PG; Cartei, F; Danesi, R; Ducci, F; Fatigante, L; Laddaga, M; Tacca, M, 1994)

Research

Studies (74)

TimeframeStudies, this research(%)All Research%
pre-19903 (4.05)18.7374
1990's7 (9.46)18.2507
2000's11 (14.86)29.6817
2010's50 (67.57)24.3611
2020's3 (4.05)2.80

Authors

AuthorsStudies
Baxter, ME1
Miller, HA1
Chen, J1
Williams, BJ1
Frieboes, HB1
Marafi, F2
Sasikumar, A2
Alfeeli, M1
Fathallah, W2
Hoj, JP1
Mayro, B1
Pendergast, AM1
Arneson, K1
Mondschein, J1
Stavas, M1
Cmelak, AJ1
Attia, A1
Horn, L1
Niermann, K1
Puzanov, I1
Chakravarthy, AB1
Xia, F1
Suzuki, Y1
Nakamura, Y1
Yamada, K1
Kurabe, S1
Okamoto, K1
Aoki, H1
Kitaura, H1
Kakita, A1
Fujii, Y1
Huber, VJ1
Igarashi, H1
Kwee, IL1
Nakada, T1
Clavreul, A1
Pourbaghi-Masouleh, M1
Roger, E1
Lautram, N1
Montero-Menei, CN1
Menei, P1
Esmail, A1
Santidrian, AF1
Matsuno-Yagi, A1
Ritland, M1
Seo, BB1
LeBoeuf, SE1
Gay, LJ1
Yagi, T1
Felding-Habermann, B1
Vickers, MM1
Al-Harbi, H1
Choueiri, TK2
Kollmannsberger, C2
North, S2
MacKenzie, M2
Knox, JJ2
Rini, BI2
Heng, DY2
Galanis, E1
Anderson, SK1
Lafky, JM1
Uhm, JH1
Giannini, C1
Kumar, SK1
Kimlinger, TK1
Northfelt, DW1
Flynn, PJ1
Jaeckle, KA1
Kaufmann, TJ1
Buckner, JC1
Zustovich, F1
Landi, L1
Lombardi, G1
Porta, C2
Galli, L1
Fontana, A1
Amoroso, D1
Galli, C1
Andreuccetti, M1
Falcone, A1
Zagonel, V1
Guerin, M1
Salem, N1
Walz, J1
Dermeche, S1
Gravis, G1
Legault, G2
Kieran, MW1
Scott, RM1
Chordas, C1
Milla, SS2
Karajannis, MA2
Lee, J1
Yuasa, T1
Pal, SK1
Srinivas, S1
Bjarnason, GA1
Vaishampayan, UN1
Tan, MH1
Rha, SY1
Donskov, F1
Agarwal, N1
Wood, LA1
Hassler, MR1
Ackerl, M1
Flechl, B1
Sax, C1
Wöhrer, A1
Widhalm, G1
Dieckmann, K1
Hainfellner, J1
Preusser, M1
Marosi, C1
Hottinger, AF1
Ben Aissa, A1
Espeli, V1
Squiban, D1
Dunkel, N1
Vargas, MI1
Hundsberger, T1
Mach, N1
Schaller, K1
Weber, DC1
Bodmer, A1
Dietrich, PY1
Fisher, MJ1
Cohen, KJ1
Wisoff, JH1
Harter, DH1
Goldberg, JD1
Hochman, T1
Merkelson, A1
Bloom, MC1
Sievert, AJ1
Resnick, AC1
Dhall, G1
Jones, DT1
Korshunov, A1
Pfister, SM1
Eberhart, CG1
Zagzag, D1
Allen, JC1
Massarweh, S1
Moss, J1
Wang, C1
Romond, E1
Slone, S1
Weiss, H1
Karabakhtsian, RG1
Napier, D1
Black, EP1
Bambury, RM1
Morris, PG1
Hamed, HA1
Tavallai, S1
Grant, S1
Poklepovic, A1
Dent, P1
Barszczyk, M1
Buczkowicz, P1
Castelo-Branco, P1
Mack, SC1
Ramaswamy, V1
Mangerel, J1
Agnihotri, S1
Remke, M1
Golbourn, B1
Pajovic, S1
Elizabeth, C1
Yu, M1
Luu, B1
Morrison, A1
Adamski, J1
Nethery-Brokx, K1
Li, XN1
Van Meter, T1
Dirks, PB1
Rutka, JT1
Taylor, MD1
Tabori, U1
Hawkins, C1
Greenall, SA1
Donoghue, JF1
Van Sinderen, M1
Dubljevic, V1
Budiman, S1
Devlin, M1
Street, I1
Adams, TE1
Johns, TG1
Sie, M1
den Dunnen, WF1
Lourens, HJ1
Meeuwsen-de Boer, TG1
Scherpen, FJ1
Zomerman, WW1
Kampen, KR1
Hoving, EW1
de Bont, ES1
Eichelberg, C1
Vervenne, WL1
De Santis, M1
Fischer von Weikersthal, L1
Goebell, PJ1
Lerchenmüller, C1
Zimmermann, U1
Bos, MM1
Freier, W1
Schirrmacher-Memmel, S1
Staehler, M1
Pahernik, S1
Los, M1
Schenck, M1
Flörcken, A1
van Arkel, C1
Hauswald, K1
Indorf, M1
Gottstein, D1
Michel, MS1
Thoma, C1
Ferrandon, S1
Malleval, C1
El Hamdani, B1
Battiston-Montagne, P1
Bolbos, R1
Langlois, JB1
Manas, P1
Gryaznov, SM1
Alphonse, G1
Honnorat, J1
Rodriguez-Lafrasse, C1
Poncet, D1
Albiges, L1
Escudier, B2
Zou, Z1
Yin, Y1
Lin, J1
Hsu, LC1
Brandon, VL1
Yang, F1
Jove, R1
Jandial, R1
Li, G1
Chen, MY1
Liu, X1
Sun, K1
Wang, H1
Dai, Y1
Bell, JB1
Eckerdt, FD1
Alley, K1
Magnusson, LP1
Hussain, H1
Bi, Y1
Arslan, AD1
Clymer, J1
Alvarez, AA1
Goldman, S1
Cheng, SY1
Nakano, I1
Horbinski, C1
Davuluri, RV1
James, CD1
Platanias, LC1
Riedel, M1
Struve, N1
Müller-Goebel, J1
Köcher, S1
Petersen, C1
Dikomey, E1
Rothkamm, K1
Kriegs, M1
Valcamonico, F1
Ferrari, V1
Amoroso, V1
Rangoni, G1
Simoncini, E1
Marpicati, P1
Vassalli, L1
Grisanti, S1
Marini, G1
Sire, M1
Wallerand, H1
Kilkoski, F1
Grenier, N1
Ferrière, JM1
Ravaud, A1
Hill, KL1
Lipson, AC1
Sheehan, JM1
Zimmermann, K1
Schmittel, A1
Steiner, U1
Asemissen, AM1
Knoedler, M1
Thiel, E1
Miller, K1
Keilholz, U1
Massard, C1
Zonierek, J1
Gross-Goupil, M1
Fizazi, K1
Szczylik, C1
Walid, MS1
Johnston, KW1
Hashizume, R1
Gupta, N1
Pouessel, D2
Patard, JJ1
Culine, S2
Reardon, DA1
Vredenburgh, JJ1
Desjardins, A1
Peters, K1
Gururangan, S1
Sampson, JH1
Marcello, J1
Herndon, JE1
McLendon, RE1
Janney, D1
Friedman, AH1
Bigner, DD2
Friedman, HS1
Siegelin, MD1
Raskett, CM1
Gilbert, CA1
Ross, AH2
Altieri, DC1
Sheng, Z2
Li, L1
Zhu, LJ1
Smith, TW1
Demers, A1
Moser, RP1
Green, MR2
Hainsworth, JD1
Ervin, T1
Friedman, E1
Priego, V1
Murphy, PB1
Clark, BL1
Lamar, RE1
Lemasson, B2
Serduc, R2
Maisin, C2
Bouchet, A2
Coquery, N1
Robert, P1
Le Duc, G2
Troprès, I1
Rémy, C2
Barbier, EL2
Coriat, R1
Mir, O1
Ropert, S1
Clerc, J1
Goldwasser, F1
Verma, J1
Jonasch, E1
Allen, P1
Tannir, N1
Mahajan, A1
Nabors, LB2
Supko, JG2
Rosenfeld, M1
Chamberlain, M1
Phuphanich, S2
Batchelor, T1
Desideri, S1
Ye, X2
Wright, J1
Gujar, S1
Grossman, SA2
Wolff, JE1
Brown, RE1
Buryanek, J1
Pfister, S1
Vats, TS1
Rytting, ME1
Jagannathan, JP1
Ramaiya, NH1
Shinagare, AB1
Hornick, JL1
George, S1
Du, W1
Zhou, JR1
Wang, DL1
Gong, K1
Zhang, QJ1
Den, RB1
Kamrava, M1
Werner-Wasik, M1
Dougherty, E1
Marinucchi, M1
Lawrence, YR1
Hegarty, S1
Hyslop, T1
Andrews, DW1
Glass, J1
Friedman, DP1
Camphausen, K1
Dicker, AP1
Shen, Y1
Ruan, M1
Luo, Q1
Yu, Y1
Lu, H1
Zhu, R1
Chen, L1
Christen, T1
Lee, EQ1
Kuhn, J1
Lamborn, KR1
Abrey, L1
DeAngelis, LM1
Lieberman, F1
Robins, HI1
Chang, SM1
Yung, WK1
Drappatz, J1
Mehta, MP1
Levin, VA1
Aldape, K1
Dancey, JE1
Wright, JJ1
Prados, MD1
Cloughesy, TF1
Gilbert, MR1
Wen, PY1
Vanhuyse, M1
Penel, N1
Caty, A1
Fumagalli, I1
Alt, M1
Zini, L1
Adenis, A1
Dudek, AZ1
Raza, A1
Chi, M1
Singhal, M1
Oberoi, R1
Mittapalli, RK1
Agarwal, S1
Elmquist, WF1
Carra, E1
Barbieri, F1
Marubbi, D1
Pattarozzi, A1
Favoni, RE1
Florio, T1
Daga, A1
Peereboom, DM1
Ahluwalia, MS1
Hilderbrand, SL1
Rosenfeld, MR1
Mikkelsen, T1
Simon, JM1
Noël, G1
Chiras, J1
Hoang-Xuan, K1
Delattre, JY1
Baillet, F1
Mazeron, JJ1
Jane, EP1
Premkumar, DR1
Pollack, IF1
Imarisio, I1
Paglino, C1
Gudena, V1
Verma, N1
Post, G1
Kizziah, M1
Fenning, R1
Montero, AJ1
van der Maazen, RW1
Thijssen, HO1
Kaanders, JH1
de Koster, A1
Keyser, A1
Prick, MJ1
Grotenhuis, JA1
Wesseling, P1
van der Kogel, AJ1
Cartei, F1
Danesi, R1
Ducci, F1
Fatigante, L1
Caciagli, PG1
Tacca, M1
Laddaga, M1
Lambin, P1
Poortmans, P1
Menten, J1
Hamers, HP1
Salford, LG1
Brun, A1
Kjellén, E1
Pero, RW1
Persson, RB1
Hulshof, MC1
Rehmann, CJ1
Booij, J1
van Royen, EA1
Bosch, DA1
González González, D1
Brown, SL1
Ewing, JR1
Kolozsvary, A1
Butt, S1
Cao, Y1
Kim, JH1
Miralbell, R1
Mornex, F1
Greiner, R1
Bolla, M1
Storme, G1
Hulshof, M1
Bernier, J1
Denekamp, J1
Rojas, AM1
Pierart, M1
van Glabbeke, M1
Mirimanoff, RO2
Sun, LQ1
Coucke, PA1
Buchegger, F1
Wikstrand, CJ1
Mahaley, MS1
Shevaga, VN1
Coper, H1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857]Phase 212 participants (Actual)Interventional2011-04-30Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA)
Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma[NCT00884416]Phase 117 participants (Actual)Interventional2009-03-31Completed
A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer[NCT00525161]Phase 211 participants (Actual)Interventional2007-10-31Terminated (stopped due to Slow accrual and loss of funding)
A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma[NCT00732914]Phase 3272 participants (Actual)Interventional2009-01-31Completed
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307]Phase 3903 participants (Actual)Interventional2003-11-30Completed
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493]Phase 232 participants (Actual)Interventional2007-09-30Completed
A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme[NCT00544817]Phase 247 participants (Actual)Interventional2007-04-30Completed
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme[NCT00445588]Phase 256 participants (Actual)Interventional2007-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Objective Response Rates

Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Response Rate to Sorafenib

To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Clinical Benefit Rate

Clinical benefit rate is defined as complete response, partial response, or stable disease (CR/PR/SD) as measured by Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for a minimum of at least 24 weeks. (NCT00525161)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
Sorafenib & Endocrine Therapy50

Time to Progression

(NCT00525161)
Timeframe: continuously

Interventionmonths (Median)
Sorafenib & Endocrine Therapy6.1

Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Patients were followed monthly for clinical and toxicity evaluation. Disease response by RECIST criteria v1.0 was assessed after 3 months by appropriate scans and these were obtained every 2 months thereafter until progression. (NCT00525161)
Timeframe: 12 weeks after treatment & 8 weeks after initial documentation of response

Interventionparticipants (Number)
Stable DiseaseProgression
Sorafenib & Endocrine Therapy73

Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population

Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)542
Placebo436

Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population

Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)542
Placebo461

Final Progression-Free Survival (PFS) - Independent Radiological Review

PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006)167
Placebo84

Best Overall Response - Independent Radiological Review

Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

,
Interventionpercentage of participants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot Evaluated
Placebo0.00.055.230.314.5
Sorafenib (Nexavar, BAY43-9006)0.02.177.98.711.3

Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment

"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

,
InterventionScores on a scale (Least Squares Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 4, Day 1Cycle 5, Day 1Cycles 1-5 (Overall)
Placebo27.7827.2826.7826.2827.20
Sorafenib (Nexavar, BAY43-9006)27.7727.2726.7726.2727.19

Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment

"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

,
InterventionScores on a scale (Least Squares Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 4, Day 1Cycle 5, Day 1Cycles 1-5 (Overall)
Placebo21.1620.7220.2819.8420.65
Sorafenib (Nexavar, BAY43-9006)21.2120.7720.3319.8920.70

6 Month Progression Free Survival (PFS)

Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Sorafenib + Temozolomide9.4

Pharmacokinetics: AUC-24

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionug*H/L (Geometric Mean)
EIAEDs-Day 145309.7
EIAEDs-Day 2847148.2
Non-EIAEDs-Day 145238.7
Non-EIAEDs-Day 28128820.8

Pharmacokinetics: C-max

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionug/L (Geometric Mean)
EIAEDs-Day 13397.3
EIAEDs-Day 283813.9
Non-EIAEDs-Day 13155.1
Non-EIAEDs-Day 288118.8

Pharmacokinetics: T-max

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionhours (Median)
EIAEDs-Day 18.2
EIAEDs-Day 282.1
Non-EIAEDs-Day 124.0
Non-EIAEDs-Day 284.2

Safety and Toxicity of Combination

Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months

Interventionparticipants (Number)
Sorafenib + Temozolomide19

Objective Response

"The number of patients with complete or partial responses measured from the time of initial response to documented tumor progression. Radiologic response was defined using the Macdonald criteria.~The Macdonald criteria divides response into 4 types of response based on imaging (MRI) and clinical features, as follows: 1) complete response (CR); 2) partial response (PR); 3) stable disease (SD); and 4) progression (PD).~Criteria:~CR: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions. No corticosteroids, clinically stable or improved.~PR: >=50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no new lesions. Stable or reduced corticosteroids, clinically stable or improved.~SD: does not qualify for complete response, partial response or progression. Clinically stable.~PD: >= 25% increase in enhancing lesions, any new lesions. Clinical deterioration." (NCT00544817)
Timeframe: every 8 weeks until disease progression, estimated 18 months

Interventionparticipants (Number)
Combination Therapy13

Overall Survival

Defined as Day 1 of protocol treatment to date of death from any cause. (NCT00544817)
Timeframe: 18 months

InterventionMonths (Median)
Combination Therapy12

Progression-free Survival

Defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00544817)
Timeframe: 18 months

InterventionMonths (Median)
Combination Therapy6

6months -Progression-free Survival Rate

defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up (NCT00445588)
Timeframe: At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up

Interventionpercentage of participants (Number)
Treatment14

Overall Survival

death. measured by time of first day of treatment until date of death, assessed up to 2 years. (NCT00445588)
Timeframe: Time of first day of the treatment to death, assessed up to 2 years

Interventionmonths (Median)
Treatment5.7

Reviews

1 review available for niacinamide and Brain Neoplasms

ArticleYear
Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery.
    Current opinion in molecular therapeutics, 2010, Volume: 12, Issue:2

    Topics: Administration, Intranasal; Animals; Blood-Brain Barrier; Brain Neoplasms; Enzyme Inhibitors; Humans

2010

Trials

20 trials available for niacinamide and Brain Neoplasms

ArticleYear
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
    Journal of neuro-oncology, 2017, Volume: 133, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female;

2017
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Anticancer research, 2013, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2013
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8

    Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide;

2014
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
    British journal of cancer, 2014, 05-27, Volume: 110, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac

2014
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Neuro-oncology, 2014, Volume: 16, Issue:10

    Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female;

2014
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
    Future oncology (London, England), 2014, Volume: 10, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Br

2014
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai

2015
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Re

2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2011, Volume: 101, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra

2011
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Cancer, 2010, Aug-01, Volume: 116, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz

2010
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progress

2011
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
    Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benze

2012
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell

2013
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
    Neuro-oncology, 2012, Volume: 14, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Femal

2012
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
    Neuro-oncology, 2013, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; E

2013
Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2003, Volume: 67, Issue:1

    Topics: Adult; Aged; Biopsy; Brain; Brain Neoplasms; Carbon Dioxide; Chi-Square Distribution; Combined Modal

2003
Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 48, Issue:2

    Topics: Analysis of Variance; Brain Neoplasms; Carbon Dioxide; Cell Hypoxia; Cerebrovascular Circulation; Gl

1998
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Brain Neoplasms; Carbon Dioxide; Cell

1999
[Studies of the NAD(P) glycohydrolase activity in human brain tumors].
    Zeitschrift fur Krebsforschung, 1967, Volume: 70, Issue:2

    Topics: Adenoma, Chromophobe; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Enzyme Induction; Epen

1967

Other Studies

53 other studies available for niacinamide and Brain Neoplasms

ArticleYear
Metabolomic differentiation of tumor core versus edge in glioma.
    Neurosurgical focus, 2023, Volume: 54, Issue:6

    Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; M

2023
18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:2

    Topics: Biological Transport; Brain Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Niacinamide; O

2020
A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis.
    Cell reports, 2019, 12-10, Volume: 29, Issue:11

    Topics: Acyltransferases; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kina

2019
Aquaporin Positron Emission Tomography Differentiates Between Grade III and IV Human Astrocytoma.
    Neurosurgery, 2018, 06-01, Volume: 82, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aquaporins; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Female;

2018
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
    Journal of experimental & clinical cancer research : CR, 2017, 09-29, Volume: 36, Issue:1

    Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell

2017
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:1

    Topics: Brain; Brain Neoplasms; Fluorine Radioisotopes; Glioblastoma; Humans; Magnetic Resonance Imaging; Ma

2020
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:3

    Topics: Acrylamides; Animals; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Cel

2013
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma,

2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
    World journal of surgical oncology, 2013, Sep-27, Volume: 11

    Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Human

2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai

2014
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neop

2014
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Ni

2014
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
    Journal of cellular physiology, 2015, Volume: 230, Issue:1

    Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Pr

2015
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Acta neuropathologica, 2014, Volume: 128, Issue:6

    Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Co

2014
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
    Oncogene, 2015, Oct-08, Volume: 34, Issue:41

    Topics: Analgesics; Animals; Antibodies, Monoclonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; ErbB Rece

2015
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Epe

2015
Kidney cancer: SWITCHing inconsequential.
    Nature reviews. Urology, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Ce

2015
Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
    Molecular cancer, 2015, Jul-17, Volume: 14

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Glioblastoma; Humans; Indol

2015
Sorafenib-Sunitinib Sequence: The Jury Is Out.
    European urology, 2015, Volume: 68, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Ce

2015
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
    Journal of neurosurgery, 2016, Volume: 124, Issue:5

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Convection; Heterografts; Humans;

2016
Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
    Cellular and molecular neurobiology, 2016, Volume: 36, Issue:7

    Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival;

2016
MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
    Molecular cancer research : MCR, 2016, Volume: 14, Issue:10

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival

2016
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv

2016
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
    Journal of neuro-oncology, 2009, Volume: 91, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cor

2009
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Bulletin du cancer, 2008, Volume: 95, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate

2008
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
    Journal of neurosurgery, 2009, Volume: 111, Issue:3

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasm

2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, R

2009
Successful treatment of a brain-metastasized renal cell carcinoma.
    German medical science : GMS e-journal, 2009, Oct-21, Volume: 7

    Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies;

2009
[Advanced renal carcinomas with special situations. How to treat them?].
    Bulletin du cancer, 2010, Volume: 97

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesul

2010
Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Neuroscience letters, 2010, Jul-12, Volume: 478, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line,

2010
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
    Nature medicine, 2010, Volume: 16, Issue:6

    Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP

2010
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
    Radiology, 2010, Volume: 257, Issue:2

    Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neopl

2010
A painful cranial bulge.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administ

2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
    Cancer, 2011, Nov-01, Volume: 117, Issue:21

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasm

2011
Intracranial metastasis from pediatric GI stromal tumor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neo

2012
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    World journal of surgical oncology, 2012, Apr-21, Volume: 10

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Respo

2012
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
    Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Human

2012
Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model.
    Radiology, 2012, Volume: 265, Issue:3

    Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Brain Neoplasms; Dextrans

2012
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Bulletin du cancer, 2012, Volume: 99, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclona

2012
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding

2013
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
    Cell cycle (Georgetown, Tex.), 2013, Feb-01, Volume: 12, Issue:3

    Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Differentiation; Cell

2013
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blottin

2006
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
    European urology, 2008, Volume: 53, Issue:2

    Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female;

2008
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
    European urology, 2008, Volume: 53, Issue:5

    Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Inci

2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
    Cancer biology & therapy, 2008, Volume: 7, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Lung Neoplasms; Ma

2008
Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1995, Volume: 35, Issue:2

    Topics: Administration, Inhalation; Aged; Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Female

1995
Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:8

    Topics: Administration, Oral; Adult; Aged; Brain Neoplasms; Chromatography, High Pressure Liquid; Combined M

1994
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1997, Volume: 43, Issue:3

    Topics: Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Glioma; Humans; Niacinamide; Oxygen; Rad

1997
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
    Annals of the New York Academy of Sciences, 1997, Dec-19, Volume: 835

    Topics: Animals; Astrocytoma; Brain Neoplasms; Cell Division; Combined Modality Therapy; DNA Repair; Enzyme

1997
Magnetic resonance imaging of perfusion in rat cerebral 9L tumor after nicotinamide administration.
    International journal of radiation oncology, biology, physics, 1999, Feb-01, Volume: 43, Issue:3

    Topics: Animals; Brain Neoplasms; Cerebrovascular Circulation; Magnetic Resonance Imaging; Male; Niacinamide

1999
Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice.
    Radiation research, 2001, Volume: 155, Issue:1 Pt 1

    Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Cell Division; Combined Modali

2001
Surface antigenic characteristics of human glial brain tumor cells.
    Cancer research, 1977, Volume: 37, Issue:12

    Topics: Antibodies, Neoplasm; Antibody Specificity; Antigens, Neoplasm; Brain Neoplasms; Cell Line; Cell Mem

1977
[Vitamin PP metabolism in brain tumor patients before and after surgical intervention].
    Vrachebnoe delo, 1975, Issue:2

    Topics: Adolescent; Adult; Brain Neoplasms; Child; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal;

1975